![conference banner](/images/conference-banner.jpeg)
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease and is more prevalent in patients with type 2 diabetes mellitus (T2DM). Incretin-based antidiabetic agents (glucagonlike peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors) are used in the treatment of T2DM but it is unclear whether they may also play a role in the management of NAFLD. We systematically reviewed the PubMed and Scopus database up to October 2014 and also hand-searched the references of the retrieved articles for studies evaluating the effects of these agents on NAFLD. In animal studies, both GLP-1 receptor agonists and DPP-4 inhibitors reduced transaminase activity and steatosis but their effects on liver inflammation were inconsistent and fibrosis was not assessed. In clinical studies, both agents consistently reduced transaminase activity and steatosis as assessed non-invasively. There are very limited data on the effects of incretin-based treatments on liver histology. In conclusion, GLP-1 receptor agonists and DPP-4 inhibitors appear to hold promise in patients with NAFLD but larger controlled studies with histological and clinical endpoints are needed to evaluate their effects in this population.
Keywords: Glucagon-like peptide-1 analogues, dipeptidyl peptidase-4 inhibitors, non-alcoholic fatty liver disease, steatosis, type 2 diabetes mellitus.
Current Vascular Pharmacology
Title:Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease
Volume: 13 Issue: 5
Author(s): Theodora Nakouti, Apostolos K.A. Karagiannis, Konstantinos Tziomalos and Evangelos Cholongitas
Affiliation:
Keywords: Glucagon-like peptide-1 analogues, dipeptidyl peptidase-4 inhibitors, non-alcoholic fatty liver disease, steatosis, type 2 diabetes mellitus.
Abstract: Non-alcoholic fatty liver disease (NAFLD) is the commonest chronic liver disease and is more prevalent in patients with type 2 diabetes mellitus (T2DM). Incretin-based antidiabetic agents (glucagonlike peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors) are used in the treatment of T2DM but it is unclear whether they may also play a role in the management of NAFLD. We systematically reviewed the PubMed and Scopus database up to October 2014 and also hand-searched the references of the retrieved articles for studies evaluating the effects of these agents on NAFLD. In animal studies, both GLP-1 receptor agonists and DPP-4 inhibitors reduced transaminase activity and steatosis but their effects on liver inflammation were inconsistent and fibrosis was not assessed. In clinical studies, both agents consistently reduced transaminase activity and steatosis as assessed non-invasively. There are very limited data on the effects of incretin-based treatments on liver histology. In conclusion, GLP-1 receptor agonists and DPP-4 inhibitors appear to hold promise in patients with NAFLD but larger controlled studies with histological and clinical endpoints are needed to evaluate their effects in this population.
Export Options
About this article
Cite this article as:
Nakouti Theodora, Karagiannis K.A. Apostolos, Tziomalos Konstantinos and Cholongitas Evangelos, Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease, Current Vascular Pharmacology 2015; 13 (5) . https://dx.doi.org/10.2174/1570161112666141121112612
DOI https://dx.doi.org/10.2174/1570161112666141121112612 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Scientific and Clinical Challenges in Sepsis
Current Pharmaceutical Design Effect of Danggui-Shaoyao-San-Containing Serum on the Renal Tubular Epithelial-Mesenchymal Transition of Diabetic Nephropathy
Current Pharmaceutical Biotechnology Evaluating Quinacrine as a Potential Amyloid Imaging Compound: Studies on Hen Egg White Lysozyme as Model System
Protein & Peptide Letters Further Perspectives on Diabetes: NeuroRegulation of Blood Glucose
Neuroscience and Biomedical Engineering (Discontinued) Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets Autism: Pathophysiology and Promising Herbal Remedies
Current Pharmaceutical Design Chronic Kidney Disease and the Search for New Biomarkers for Early Diagnosis
Current Medicinal Chemistry Association between HbA1C (Glycated Hemoglobin) and Clinical Outcomes in Patients with Subarachnoid Hemorrhage After Neuro-intervention
Current Neurovascular Research Fetal Undernutrition and the Programming of Blood Pressure
Current Nutrition & Food Science Feasibility of a Scale-down Production of [<sup>68</sup>Ga]Ga-NODAGA-Exendin-4 in a Hospital Based Radiopharmacy
Current Radiopharmaceuticals Fatty Acid-Mediated Inhibition of Metal Binding to the Multi-Metal Site on Serum Albumin: Implications for Cardiovascular Disease
Current Topics in Medicinal Chemistry Paramutation: Just a Curiosity or Fine Tuning of Gene Expression in the Next Generation?
Current Genomics Diabetes and Periodontal Diseases: Interplay and Links
Current Diabetes Reviews Insulin Resistance and Polycystic Ovary Syndrome Through Life
Current Pharmaceutical Design Invokana (Canagliflozin) as a Dual Inhibitor of Acetylcholinesterase and Sodium Glucose Co-Transporter 2: Advancement in Alzheimer’s Disease- Diabetes Type 2 Linkage via an Enzoinformatics Study
CNS & Neurological Disorders - Drug Targets An Osteoblastic Inflammatory Redox Model, using TNF-a, Glucose and Glucose- Oxidized Low- Density Lipoprotein: Targets for Minocycline
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Nephrotoxicity Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Drug Safety The Endothelial-Mesenchymal Transition (EndMT) and Tissue Regeneration
Current Stem Cell Research & Therapy Perception or Reality of Body Weight: Which Matters the Most to Adolescents’ Emotional Well-being?
Current Psychiatry Reviews Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews